W Michael Hooten1, David O Warner2. 1. Department of Anesthesiology, Mayo College of Medicine, Rochester, MN, United States. Electronic address: hooten.william@mayo.edu. 2. Department of Anesthesiology, Mayo College of Medicine, Rochester, MN, United States.
Abstract
BACKGROUND AND OBJECTIVES: The objectives of this randomized, single-blinded, placebo-controlled pilot trial were to investigate the effects of varenicline on opioid withdrawal among chronic pain patients undergoing opioid detoxification in an interdisciplinary pain program and the feasibility of varenicline use in this population. METHODS:Twenty-one patients were recruited (varenicline=10, placebo=11), and 7 patients in the varenicline and 11 in the placebo group completed the study. Opioid withdrawal was quantified using the Clinical Opiate Withdrawal Scale, and varenicline-related adverse effects were assessed. RESULTS:Opioid withdrawal scores tended to decrease over the course of opioid tapering in those receiving varenicline and increase in those receiving placebo. Varenicline was well-tolerated in this population, with no adverse drug effects (including nausea) observed and no effect on improvements in pain severity and depression. CONCLUSIONS: This randomized pilot study provides preliminary data for future trials of varenicline in opioid-dependent adults with chronic pain undergoing medically directed opioid detoxification.
RCT Entities:
BACKGROUND AND OBJECTIVES: The objectives of this randomized, single-blinded, placebo-controlled pilot trial were to investigate the effects of varenicline on opioid withdrawal among chronic painpatients undergoing opioid detoxification in an interdisciplinary pain program and the feasibility of varenicline use in this population. METHODS: Twenty-one patients were recruited (varenicline=10, placebo=11), and 7 patients in the varenicline and 11 in the placebo group completed the study. Opioid withdrawal was quantified using the Clinical Opiate Withdrawal Scale, and varenicline-related adverse effects were assessed. RESULTS: Opioid withdrawal scores tended to decrease over the course of opioid tapering in those receiving varenicline and increase in those receiving placebo. Varenicline was well-tolerated in this population, with no adverse drug effects (including nausea) observed and no effect on improvements in pain severity and depression. CONCLUSIONS: This randomized pilot study provides preliminary data for future trials of varenicline in opioid-dependent adults with chronic pain undergoing medically directed opioid detoxification.
Authors: Nicholas Avery; Amy G McNeilage; Fiona Stanaway; Claire E Ashton-James; Fiona M Blyth; Rebecca Martin; Ali Gholamrezaei; Paul Glare Journal: BMJ Date: 2022-04-04
Authors: Annely I Langejan; Loes de Kleijn; Hanneke J B M Rijkels-Otters; Stan F J Chudy; Alessandro Chiarotto; Bart W Koes Journal: Fam Pract Date: 2022-03-24 Impact factor: 2.290
Authors: Alice Bruneau; Clarice Poirier; Mélanie Bérubé; Aline Boulanger; Céline Gélinas; Line Guénette; Anaïs Lacasse; David Lussier; Yannick Tousignant-Laflamme; M Gabrielle Pagé; Marc O Martel Journal: Can J Psychiatry Date: 2022-03-15 Impact factor: 5.321